RushNet, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
February 10, 2023 at 10:02 pm IST
Share
RushNet, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 1.98 million compared to USD 1.55 million a year ago. Net income was USD 0.214359 million compared to USD 0.242463 million a year ago. Basic earnings per share from continuing operations was USD 0.00003 compared to USD 0.00002 a year ago. Diluted earnings per share from continuing operations was USD 0.00003 compared to USD 0.00002 a year ago.
For the six months, revenue was USD 3.37 million compared to USD 2.92 million a year ago. Net loss was USD 0.042729 million compared to net income of USD 0.653776 million a year ago. Basic loss per share from continuing operations was USD 0.00001 compared to basic earnings per share from continuing operations of USD 0.00006 a year ago. Diluted loss per share from continuing operations was USD 0.00001 compared to diluted earnings per share from continuing operations of USD 0.00006 a year ago.
RushNet, Inc. operates under the name HeliosDX. HeliosDX is a national clinical reference laboratory offering high-complexity urine drug testing (UDT), behavioral drug testing, allergy droplet cards, oral fluids, and infectious disease (PCR). The Company provides management services and insurance billing services principally to clinical reference laboratories. It provides PGX testing through Leo Partners. It provides oral fluid toxicology testing for a range of drugs. The Quantisal Collection Procedure makes taking the sample quick and easy. HeliosDX also offers a preliminary 10-panel plus adulteration detection screen, as well as confirmation testing via its comprehensive toxicology panel. Its subsidiaries include Chattahoochee Physicians Laboratory Services, LLC; doing business as HeliosDx and Grandeza Healthcare Consultants, LLC.